Viral Filtration: A Review of Current and Future Practices in Bioprocessing
AUTHOR NAMES: Sarah A Johnson1; Shuang Chen2; Glen Bolton3; Qi Chen4; Scott Lute1; John Fisher4; Kurt Brorson5
AUTHOR ADDRESSES:
  1. Office of Biotechnology Products, CDER, FDA 10903 New Hampshire Ave., Silver Spring Maryland
  2. NGM Biopharmaceuticals Inc., South San Francisco CA
  3. Amgen Inc., Cambridge MA
  4. Genentech Inc. South San Francisco CA
  5. Parexel International., Newton MA
AUTHOR EMAIL ADDRESS: ’Johnson, Sarah (CDER)’ <Sarah.Johnson1@fda.hhs.gov>; Shuang Chen <schen@ngmbio.com>; Bolton, Glen <gbolton@amgen.com>; Qi Chen <chen.qi@gene.com>; Lute, Scott <Scott.Lute@fda.hhs.gov>; John Fisher fisher.john@gene.com; Kurt Brorson <kurt.brorson@parexel.com>
CORRESPONDING AUTHOR: Kurt Brorson <kurt.brorson@parexel.com>